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Infections of the neonate due to the group B Streptococcus have been recognized since the
1930s, but it was during the 1970s that their incidence grew alarminglythroughout the world. A
research effort stimulated by this problem has yielded significant new information about many
facets of the pathogenesis of these infections. Immunologic investigations have pinpointed a
lack of transplacentally acquired antibody as a significant risk factor. In the laboratory, assays
of antibody which have a functional endpoint have demonstrated that the type-specific car-
bohydrate antigens play a major role in stimulating the development of protective antibody.
These assays have been shown to correlate with certain tests of primary antigen-antibody in-
teraction which do not have a functional endpoint, but are simpler to use in larger scale
epidemiologic studies. These tools may be useful in filling the gaps in our current knowledge of
the pathogenesis of this infection.
... The changes in etiology [of neonatal sepsis] are indeed interesting-
particularly the rise in Group B strep infections. Why? What is your answer
to this shift? How often are group B found in the throat compared to the
genital tract? Plenty of questions for you to tackle!
Yours,
Dorothy*
In the 1970s, a number of "new" diseases were discovered, most of which were
known but had been poorly defined in the past. Such "new" diseases included infant
botulism; Legionnaire's disease; Pneumocystis carinii pneumonia in the immuno-
suppressed; Clostridium difficile toxin-associated, antibiotic-induced pseudomem-
branous colitis; and rotavirus, yersinia, and campylobacter as agents of acute diar-
rhea. Group B streptococcus (GBS) was recognized as an agent of human disease in
the 1930s [1,2], but it has clearly grown in importance during the 1970s. Unlike these
other agents, the type of disease and spectrum of common syndromes caused by
GBS were apparent to some investigators prior to the 1970s [3], but, as in the case of
these "new diseases," research stimulated by an alarming increase in incidence has
revolutionized our concept of the pathogenesis of the disease. Despite this new in-
formation, we are still unable to account for the rise in incidence which resulted in a
worldwide pandemic of neonatal sepsis and meningitis due to this agent.
Clearly the increase in group B streptococcal infections of infants is not a matter
of increased recognition but of increased incidence. The causative agent had been
isolated and identified using routinely available media and methods long before the
1970s [3] and longitudinal observations at several institutions where neonatal sepsis
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has been a continuing interest demonstrates this increase. At Yale-New Haven
Hospital, records of the bacteriology of neonatal sepsis have been kept since 1928.
Prior to 1970 only 14 cases of GBS septicemia were documented. In the years
1970-1978, there were 90 newborns with GBS bacteremia [4] and the vast majority
had life-threatening sepsis [5]. At Yale the highest incidence of GBS infection was
seen in 1977 (Table 1) and the incidence had only declined slightly by the end of the
decade.
MORE QUESTIONS THAN ANSWERS
In 1973 [6] and again in 1976 [7], the clinical experience at Yalewith GBS neonatal
infections was reviewed in publications. An editorial by Feigin accompanying the
second of these reviews listed what he saw as the most vitally needed information
about pathogenesis and treatment of neonatal infections due to this species [8]. He
referred to the important publications of the early 1970s delineating the major syn-
dromes and posed these, at that time, unanswered questions (which I paraphrase):
1. To what extent does maternal group B streptococcal carriage or infection cause
fetal or neonatal morbidity or mortality or both?
2. Should the pediatrician treat all infants born to mothers who at term have
vaginal cultures that are positive for group B streptococci?
3. What is the role of maternal antibody in protecting the mother from group B
streptococcal carriage or infection?
4. What is the role of transplacentally acquired antibody in protecting the
newborn infant from early-onset or late-onset group B streptococcal diseases?
5. Which antibodies are important and what specific concentrations are critical?
6. Does group B streptococcal infection or carriage in the newborn infant
stimulate the production of antibody?
7. Is the detection ofantibody useful in the diagnosis ofinfection due to group B
streptococci?
8. What is the role of cellular immunity in limiting the extent of or preventing
neonatal group B streptococcal septicemia?
In a relatively short time studies designed to answer each of these questions have
appeared. While it is probably true that the final word on none ofthem is available,
we have come a long way. The state of the art was recently reviewed by Baker [9],
but already the questions relating to antibiotic prophylaxis and the role of the
vaginal carrier have been addressed in important newer studies. The questions
numbered 4 and 5 above concern protection by transplacentally acquired antibody,
the specificity ofantibody, and the potency ofantibody. I shall review the newer in-
formation and methodology used to answer these critical questions.
FUNCTIONAL ANTIBODY TO GROUP B STREPTOCOCCUS:
IN VITRO AND ANIMAL STUDIES
The presence of antibody to group B Streptococcus can be measured in the
laboratory using serologic tests of primary antigen-antibody interaction such as im-
TABLE 1
Incidence of Group B Streptococcal Infections in Infants at Yale-New Haven Hospital 1970-1979
Year 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979
Incidencea 0.41 0.44 1.69 1.01 1.91 1.94 2.08 2.45 1.50 1.56
aCases of group B streptococcal bacteremia and/or meningitis per 1,000 live births. (Data from [5].)
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munoprecipitation or a radioactive antigen binding assay (RABA) [10] or indirectly
as in indirect immunofluorescence [11]. While these tests have demonstrated an-
tibody in animals and humans, functional tests of antibody have been used to in-
vestigate the antigenic specificity of antibody and the antigens involved in the pro-
tective antibody response. Animal protection studies to investigate GBS antibody
response were pioneered by Lancefield using rabbit antisera to protect adult mice
from lethal infection. Lancefield and associates were able to show that antibody to
the type-specific carbohydrates of types Ia, Ib, and Ic is protective, and antibody to
other antigenic determinants were responsible for weaker cross-protection between
serotypes. Other animal models ofprotection include the infant rat [12], infant mice
[13], and chicken embryos [14].
An in vitro model of protection, the opsonophagocytic assay, was utilized by
Baltimore et al. to demonstrate type-specific antibody in rabbit antisera to all five
serotypes of GBS: Ia, Tb, Ic, II, and III. They demonstrated the functional cross-
reaction due to the shared Ibc protein and the Iac carbohydrate [15]. Since
Lancefield had never reported on a mouse protection test for GBS serotype III, the
serotype of major importance in human neonatal infections, this was the first
demonstration that antibodies to type III are functional and serotype-specific. In
this study it was also demonstrated that antibody to type Ia also opsonized type III
strains, a finding not previously reported but confirmed subsequently in the chicken
embryo protection test [14] and in the mouse protection test when Baltimore et al.
developed the methods to enhance the virulence of GBS type III in mice [16].
FUNCTIONAL ANTIBODY TO GROUP B
STREPTOCOCCUS: HUMAN SERA
At the time Baltimore et al. reported on the opsonophagocytic assay for
demonstration of the antigens to which rabbit antibodies were directed [15], Hem-
ming and associates reported that opsonic antibody could be measured in human
sera as well, using thetechnique ofneutrophil chemiluminescence [17]. They showed
that most newborns born to women colonized vaginally with GBS had serum op-
sonins but infants who developed sepsis or meningitis lacked opsonins in the serum.
This finding has been confirmed by others, using a number ofnon-functional assays
and with larger numbers of human subjects. One of these studies, by Baker and
Kasper, measured antibody binding to the serotype III-specific carbohydrate in a
RABA. The blood of mothers whose babies developed GBS infections was
significantly deficient in antibody compared with the maternal blood of babies
whose mothers were colonized with GBS but who escaped invasive infection [18].
They felt that protective antibody was directed specifically to this type-specific car-
bohydrate. Functional assays have lent support to this thesis. Baltimore et al.
demonstrated that the antigen used in this RABA absorbed out all activity of the
rabbit antiserum to GBS serotype III from rabbits immunized with the whole
organism [15], and all mouse-protective activity from this serum as well [16]. These
serum absorptions were serotype-specific. The RABA was "validated" as predictive
of functional immunity in human sera in a demonstration of excellent correlation of
antibody concentration measured by RABA and titer of opsonins [19] and mouse
protection titer [20]. This correlation was established with sera from volunteers im-
munized with a preparation of the GBS serotype III-specific carbohydrate. While
these functional assays are neither simple to perform nor are they the most sensitive,
it is possible to determine the biologic importance of the various antigen-antibody
interactions in pathogenesis rather than chemical affinity alone. Such tests can also
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validate non-functional assays by statistical correlation. These non-functional
assays may be more suitable for use when large numbers of sera are to be studied
and when maximal reproducibility and sensitivity are required.
UNANSWERED QUESTIONS WHICH REMAIN
Human experimentation with group B streptococcal infections is not practical.
Other than immunization of volunteers with safe, non-living antigenic preparations,
no human experiments have been performed or are likely to be performed. Func-
tional assays and animal models have relevance to protection in humans and their
use has led to important discoveries about the pathogenesis of GBS disease. Such
studies have provided the rationale of vaccinating antibody-deficient women with a
carbohydrate antigen of GBS to protect by transplacental antibody. Such a vaccine
might be administered before or during pregnancy.
A number of unanswered questions still exist. Antibody studies should be helpful
in answering some ofthese questions. Answers to the following questions should im-
prove our understanding of the pathogenesis of group B streptococcal infections.
1. What was responsible for the rise in incidence ofgroup B streptococcal infec-
tion in the 1970s? Was it a change in the bacterium, the host, or the environment?
2. What is responsible for the peculiar age-specific incidence ofinfections due to
GBS? Why is the first month of life, especially the first 48 hours, the period of such
high susceptibility?
3. What is responsible for the "late-onset" infections which occur after the first
week of life until several months ofage? What protective mechanisms develop in the
infant so that after six months of age the disease is practically never seen in
childhood?
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